CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

No.: P/CV-DPTU2

Re: Explanation of profit in production and business in the financial statements of the first quarter of 2025 compared to the same period last year with the difference of over 10%

SOCIALIST REPUBLIC OF VIETNAM Independence – Freedom – Happiness

Hanoi, April 15 12025

To: - The State Securities Commission

- Hanoi Stock Exchange

Central Pharmaceutical Joint Stock Company No2 (Securities code: **DP2**) would like to send our sincere greetings and thanks for your concern to our company in the past time.

Implementing the Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding the disclosure of information on the securities market:

In the Financial statements for the first quarter of 2025 dated April 2025 of Central Pharmaceutical Joint Stock Company No2, the profit after corporate income tax for this period of this year is: - VND 3,452,857,311, compared to the same period last year: - VND 1,394,076,916.

DP2 would like to explain the profit in production and business as follow:

- In the first quarter of 2025, the Company has no other income.
- The pharmaceutical market is very difficult, so the revenue in the first quarter of 2025 decreased compared to the same period in 2024. For the above-mentioned reasons, the first quarter of 2025 suffers a higher loss than the first quarter of 2024.

DP2 respectfully hopes to receive help from your agency.

Best regards,

Recipients:

- As above:

- Archive: VT, TCKT

GENERAL DIRECTOR

CÔNG TY
CÔ PHẦN
DƯỢC PHẨM
TRUNG ƯƠNG 2

Pharmacist. Le Tien Dung